This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Pediatric Ophthalmology  • Alert me on articles by topic

Arch Ophthalmol. 2005;123:557-558.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

As physicians, we pride ourselves in our use of the scientific method to give the best care to our patients. Yet many of our daily treatment decisions reveal us more as apprentices than scientists. We choose a particular treatment not because a clinical trial determined that it worked better but because that is the way our mentors’ mentors did it. The problem is practical: randomized controlled trials, while scientifically powerful, are difficult and expensive to carry out effectively. Consider amblyopia, a well-recognized cause of vision loss in millions of our patients. Do we occlude the eye with a patch or blur with atropine? If we use atropine, do we use it daily or just on weekends? If we patch, how many hours work best? When do we stop treating? When is it too late to start?

Over the past 7 years, the Pediatric Eye Disease Investigator Group has carried out . . . [Full Text of this Article]

AUTHOR INFORMATION
David G. Hunter, MD, PhD

RELATED ARTICLE

Randomized Trial of Treatment of Amblyopia in Children Aged 7 to 17 Years
Pediatric Eye Disease Investigator Group
Arch Ophthalmol. 2005;123(4):437-447.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Amblyopia in children aged 7 to 17 years.
Phillips
Arch Ophthalmol 2006;124:1668-1668.
FULL TEXT